Teva Form 144: Insider Sales and RSU Vesting

Teva Pharmaceutical Industries reported a Form 144 notice relating to proposed sales of its ordinary shares.

Accepted by SEC EDGAR 03/03/2026 - 05:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries reported a Form 144 notice relating to proposed sales of its ordinary shares. The filing lists a restricted share unit award of 3,461 shares vesting on 03/03/2026. The filing also discloses insider sales by Brian Savage: 450 shares sold on 01/30/2026 and 1,000 shares sold on 12/12/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 report?

The Form 144 reports proposed sales of TEVA ordinary shares and related insider transactions. It lists a 3,461-share restricted share unit award vesting on 03/03/2026, and recent insider sales by Brian Savage on 01/30/2026 and 12/12/2025.

Who reported recent share sales in the TEVA Form 144?

Brian Savage is identified as the reporting party who sold shares. The filing shows he sold 450 shares on 01/30/2026 and 1,000 shares on 12/12/2025, with monetary amounts listed alongside each transaction.

Does the filing show any RSUs for TEVA and when do they vest?

Yes. The filing lists a Restricted Share Unit award of 3,461 ordinary shares tied to compensation that vests on 03/03/2026. The RSU is recorded under the securities to be sold section of the filing.

What transaction dates and amounts appear in TEVA's Form 144?

Transaction dates shown are 12/12/2025 (1,000 shares, amount 29,910.70) and 01/30/2026 (450 shares, amount 15,178.95). The filing pairs each sale date with the share count and a monetary figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002112339
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Savage Brian
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP INTERIM CHIEF LEGAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	1274	41226.51	1149812898	03/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2023	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			3461	03/03/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BRIAN SAVAGE 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	01/30/2026	450	15178.95
BRIAN SAVAGE 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	12/12/2025	1000	29910.70

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES.
Date of Notice	03/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)